摘要
c-Kit是典型的Ⅲ型受体酪氨酸激酶,在肿瘤的发生发展以及侵袭、迁移和复发过程中起着十分重要的作用,是目前肿瘤分子靶向治疗的热门靶标之一,其抑制剂也成为抗肿瘤药物研究与开发的热点。简介c-Kit激酶及其激活型突变与肿瘤发生发展的关系,着重综述近年来已上市和处于临床试验阶段的c-Kit激酶抑制剂及其耐药机制研究。
As a typical member of type Ill receptor tyrosine kinase family, c-Kit plays a key role in tumor occurrence, development, invasion, migration and recurrence. So it is one of the hot targets for molecular targeted cancer therapy and its inhibitor has become a hot spot of research and development of antitumor drugs, c-Kit kinase and the associations between its activating mutations and tumorigenesis have been introduced. Especially, the recent researches on the c-Kit kinase inhibitors marketed and in clinical trials and their resistance mechanisms have been reviewed.
出处
《药学进展》
CAS
2014年第7期497-506,共10页
Progress in Pharmaceutical Sciences
